PE
ELVN icon

Point72 Europe’s Enliven Therapeutics ELVN Stock Holding History

Point72 Europe’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$14.6K Buy
+712
New +$14.4K ﹤0.01% 506

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Point72 Europe's ELVN Position: Q3 2025 in Review

Point72 Europe opened a new position in Enliven Therapeutics (ELVN) in Q3 2025: 712 shares worth $14.6K. The stake represents ﹤0.01% of the portfolio and ranks #506 among its holdings.

134 funds tracked by Wall St. Rank hold ELVN as of Q3 2025.

  • Point72 Europe held 712 shares of Enliven Therapeutics worth $14.6K as of Q3 2025.
  • Enliven Therapeutics was a new Point72 Europe position in Q3 2025.
  • Enliven Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #506 holding.
  • 134 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.